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Abstract
Objectives: Bilirubin has potential antioxidant and anti-inflammatory properties. The UGT1A1*28 polymorphism (TA repeats
in the promoter region) is a major determinant of bilirubin levels and recent evidence suggests that raised adiposity may
also be a contributing factor. We aimed to study the interaction between UGT1A1 polymorphism, hematological and
anthropometric variables with total bilirubin levels in young individuals.
Methods: 350 obese (mean age of 11.6 years; 52% females) and 79 controls (mean age of 10.5 years; 59% females) were
included. Total bilirubin and C-reactive protein (CRP) plasma levels, hemogram, anthropometric data and UGT1A1
polymorphism were determined. In a subgroup of 74 obese and 40 controls body composition was analyzed by dual-energy
X-ray absorptiometry.
Results: The UGT1A1 genotype frequencies were 49.9%, 42.7% and 7.5% for 6/6, 6/7 and 7/7 genotypes, respectively.
Patients with 7/7 genotype presented the highest total bilirubin levels, followed by 6/7 and 6/6 genotypes. Compared to
controls, obese patients presented higher erythrocyte count, hematocrit, hemoglobin and CRP levels, but no differences in
bilirubin or in UGT1A1 genotype distribution. Body fat percentage was inversely correlated with bilirubin in obese patients
but not in controls. This inverse association was observed either in 6/7 or 6/6 genotype obese patients. UGT1A1
polymorphism and body fat percentage were the main factors affecting bilirubin levels within obese patients (linear
regression analysis).
Conclusion: In obese children and adolescents, body fat composition and UGT1A1 polymorphism are independent
determinants of total bilirubin levels. Obese individuals with 6/6 UGT1A1 genotype and higher body fat mass may benefit
from a closer clinical follow-up.
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Introduction
Bilirubin is the ultimate product of the haem group catabolism
and serves as a diagnostic marker of liver and blood disorders [1].
Bilirubin is a water-insoluble compound that circulates bounded to
albumin and requires glucuronidation by a microsomal enzyme,
the uridine diphosphate glucuronosyltransferase (UGT) 1A1, to be
excreted. The UGT1A1 gene locus has been mapped to
chromosome 2q37 [2] and one of the most common genetic
variants that affects the glucuronidation of bilirubin is a TA
duplication polymorphism in the TATA box region of the gene
promoter. Homozygous individuals carrying the A(TA)7TAA
allele have higher levels of unconjugated bilirubin (UCB), caused
by a reduction of 30% in the UGT1A1 transcription [3]. The
estimated frequency of this allele is 0.35 in Caucasians, leading to a
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homozygous genotype in about 10% of the population, but the
frequency is highly variable in different ethnicities [4,5]. Homo-
zygosis for the TA duplication was considered as the main cause of
Gilbert syndrome in Caucasian population [3,4], and justify some
of the inter-individual variations in bilirubin levels [6].
Under certain conditions bilirubin can be toxic [7]. High
plasma concentrations are associated with deleterious effects in
new-borns, increasing the risk of neurological dysfunction [7,8], as
a result of its toxic effect on neuronal tissue. However, recent
investigation has recognized that UCB exerts anti-oxidant and
anti-inflammatory activities, and that mild hyperbilirubinaemia
might have positive health effects. UCB inhibits lipid peroxidation
[9] and suppresses inflammation in activated neonatal neutro-
phils[10], and population studies documented that individuals with
higher circulating UCB have a reduced incidence of cardiovas-
cular problems [11–13] and of carcinoma in general [14].
Furthermore, subjects with Gilbert syndrome seem to present
low levels of oxidative stress associated with hyperbilirubinemia
[15].
Obesity, a low-grade inflammatory disease [16], is increasing all
over the world and is a significant risk factor for cardiovascular
diseases (CVD). This is of particular concern in our country,
considering the very high prevalence of overweight/obesity
(31.5%) in Portuguese children when compared to other European
countries [17]. In obesity, cardiovascular morbidity and mortality
are associated with classic risk factors, namely dyslipidemia,
hypertension and impaired glucose metabolism. These risk factors,
known as predictive of CVD, are characteristic of the metabolic
syndrome (MS) [18]. Moreover, serum bilirubin levels are
inversely associated with the MS and systemic inflammation in
adults [19–21], as well as in children and adolescents [22]. In
particular, abdominal obesity per se seems to be associated with low
serum bilirubin levels [21–23]. Furthermore, a recent study
hypothesized that circulating bilirubin levels might be already
altered in overweight asymptomatic middle-aged individuals
before full development of the MS [24].
The aim of our work was to evaluate how total bilirubin (TB)
levels are influenced by UGT1A1*28 polymorphism, haematolog-
ical, biochemical and anthropometric variables in Portuguese
obese children and adolescents.
Materials and Methods
2.1. Subjects
Obese children and adolescents, aged 4–18 years, were
identified from medical records, at the outpatient clinics of
pediatric obesity in two hospitals in Porto - Portugal. A group of
children from 5 primary and 2 middle and high public schools
from Oporto suburban setting, were also recruited to this study,
providing a control group and enlarging the obese group.
The study protocol was approved by the Committee on Ethics
of Oporto Hospital Centre, the Committee on Ethics of Hospital
Sa˜o Joa˜o, the Review Committee of the Scientific Board of the
Faculty of Sport of the University of Porto as well as by the
Foundation of Science and Technology.
As referred, the main objective of this study was to investigate
total bilirubin levels in obese and non-obese subjects; thus, the
sample size was based on this main variable. Considering the
difficulty of getting blood samples from non-obese, healthy
subjects, the sample size relation between obese and controls
was set up as 4:1. Assuming that a clinical relevant difference
between experimental and control was 1 unit of bilirubin, and a
common standard deviation of 3 units of bilirubin, for a relation of
4:1, the sample size calculations, for a power of 80% and a
significant level of 5%, define, respectively, 335 obese to 89
controls. In accordance, we tried to achieve these numbers as close
as possible; a total of 350 obese children and adolescents and 79
controls participated in the study after informed and written
consent of their parents. Smokers, subjects with diabetes mellitus,
endocrine disorders, hereditary diseases, inflammatory or infec-
tious diseases or under any therapy that could interfere with our
results were excluded from the study.
2.2. Procedures and Assays
2.2.1. Anthropometric characterization and clinical
evaluation. All participants were subjected to clinical exami-
nation. Height and weight were measured. Obesity was defined as
body mass index (BMI) z-score greater than +1.65 for age and
gender, according to 2000 Centre for Disease Control and
Prevention (CDC) growth charts. Body composition was evaluated
by dual-energy X-ray absorptiometry (DEXA) in a subgroup of
participants (74 obese and 40 controls).
2.2.2. Blood samples. Blood was collected by venipuncture
in EDTA containing tubes, after overnight fasting (10–12 h) and
processed within 2 h of collection. Aliquots of buffy-coat and
plasma were made, and immediately stored at 280uC until
assayed.
2.2.3. Haematological data. Red blood cell (RBC) count,
haematocrit (Ht), haemoglobin (Hb) concentration and haemati-
metric indices [mean cell volume (MCV), mean cell Hb (MCH)
and mean cell Hb concentration (MCHC)] were measured by
using an automatic blood cell counter (ABX Micros 60-OT).
2.2.4. DNA analysis. Genomic DNA was extracted from
buffy-coat by proteinase K/salt precipitation method [25,26].
Genotyping TA duplication in the TATA box of the UGT1A1
promoter was performed by polymerase chain reaction (PCR)
(forward: 59-TAACTTGGTGTATCGATTGGTTTTTG-39; re-
verse: 59-ACAGCCATGGCGCCTTTGCT-39). PCR was fol-
lowed by electrophoresis in 15% polyacrylamide gel in a Tris/
Borate/EDTA buffer. The gel was stained with silver nitrate,
photographed and samples were classified.
2.2.5. Plasma analysis. The plasma levels of C-reactive
protein (CRP) were determined by immunoturbidimetry [CRP
(latex) High-Sensitivity, Roche Diagnostics] and quantification of
TB was performed by a colorimetric test (diazotized sulfanilic acid
reaction, Roche Diagnostics).
The determination of circulating levels of glucose and insulin
was performed by using routine automated technology (ABX
Diagnostics). Homeostasis model assessment of insulin resistance
(HOMAIR) was calculated [27].
2.3. Statistical Analysis
The distributions of continuous variables were analysed using
Kolmogorov-Smirnov tests. Normally distributed variables are
presented as mean 6 SD and those non-normally distributed are
presented as median (interquartile range). Comparisons between
two groups were performed using Student’s unpaired t-test or
Mann-Whitney U test. Adjustment for confounding factors was
performed using ANCOVA. The association between categorical
variables was analysed using chi-squared (x2) test and Fisher’s
exact test.
The strength of the association between the variables was
estimated by Pearson correlation coefficient, after log transforma-
tion of the variables (whenever necessary). To evaluate the
contribution of the different variables to TB levels, multiple
regression analysis was performed, using stepwise selection, with
an entry criteria of p,0.05.
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Statistical analysis was performed using the Statistical Package
for Social Sciences (SPSS), version 20.0 (IBM, Armonk, NY,
USA). Statistical significance was accepted at p less than 0.05.
Results
The anthropometric data, UGT1A1 genotypes and haemato-
logical parameters of the obese children and adolescents (n=350)
and controls (n=79), according to gender, are presented in
Table 1.
Comparing males and females within the control group, body
fat and trunk fat percentages were significantly lower for boys,
whereas RBC count, Hb levels and MCHC values were
significantly higher. Within obese patients, RBC count, Hb levels
and Ht values were significantly higher for boys, whereas insulin
levels and HOMAIR values were lower. No statistical significant
differences were found in the distribution of subjects with respect
to UGT1A1 genotypes or in TB levels between boys and girls,
within both groups.
Compared to controls, and as expected considering the
inclusion criteria, obese patients presented significantly higher
height, weight, BMI, BMI z-score, body fat and trunk fat
percentages (p,0.001 for all). Obese patients also presented
significantly higher erythrocyte count, Ht and HOMAIR values
and Hb, insulin and CRP levels (p,0.001 for all), but no
significant differences in TB levels (p=0.222), MCV (p=0.432),
MCH (p=0.474), MCHC (p=0.603), glucose (p=0.389) or in
UGT1A1 genotype distribution (p=0.244). These results were
similar when groups were analysed separately according to gender
(Table 1), with exception for MCHC values that were slightly (but
significantly) higher in female obese patients. The ‘‘7’’ allele was
more prevalent in male controls than in male obese patients, but
this difference was not statistically significant (p=0.085).
The UGT1A1 genotype frequencies in all studied individuals
were 49.9%, 42.7% and 7.5% for 6/6, 6/7 and 7/7 genotypes,
respectively. UGT1A1*28 polymorphism was associated with
different TB levels (Figure 1A); patients with 7/7 genotype
presented the highest TB levels, followed by 6/7 and 6/6
genotypes (p,0.01 between all groups). No significant differences
in TB levels were observed between obese and control individuals,
for the different UGT1A1 genotypes (Figure 1B).
Within the control group (n=79), TB levels correlated positively
and significantly with age (r=0.304, p=0.007), height (r=0.360,
p=0.001), weight (r=0.390, p,0.001), BMI (r=0.370, p=0.001),
Ht (r=0.247, p=0.028), MCV (r=0.292, p=0.009), and corre-
lated negatively and significantly with MCHC (r=–0.258,
p=0.022). Within the obese group (n=350), TB levels correlated
positively and significantly with age (r=0.284, p,0.001), height
(r=0.285, p,0.001), weight (r=0.219, p,0.001), BMI (r=0.123,
p=0.021), Hb (r=0.305, p,0.001), Ht (r=0.352, p,0.001), MCV
(r=0.394, p,0.001), MCH (r=0.301, p,0.001) and correlated
negatively and significantly with BMI z-score (r=–0.131,
p=0.014), MCHC (r=–0.149, p=0.006) and CRP (r=–0.178,
p=0.001).
The characteristics of obese patients whose body composition
was evaluated by DEXA (n=74) are presented in Table 2. These
obese patients were divided in two groups according on having a
body fat lower or higher/equal than 42.5% (cut-off that
corresponds to the median value for the obese group). The two
groups of obese patients were matched for gender and UGT1A1
genotype distribution, but not for age. Patients presenting higher
body fat had lower bilirubin and higher CRP levels (Table 2).
These differences were similar to both sexes (Figure 2) and
remained statistically significant after adjustment for age. No
significant differences in HOMAIR values were found between the
two groups.
Associations between body and trunk fat were only accessed in
participants that evaluated their body composition by DEXA (74
obese and 40 controls). Body fat and trunk fat percentages were
negatively and significantly related with TB levels in obese patients
(r=–0.287, p=0.013 and r=–0.245, p=0.038) but not within
controls (r=0.012, p=0.941 and r=0.014, p=0.002).
Figure 1. Total bilirubin levels in all participants according to the number of TA repeats in the promoter region of UGT1A1 gene (A)
and also according to group (B), control and obese. The boxes represent the interquartile range (IQR), with the upper and lower edges of the
boxes representing the 75th and 25th percentiles, respectively. The central horizontal lines within the boxes represent median levels for each group.
The vertical whiskers above and below the boxes represent the range of outlying data points up to 1.5 times the IQR.
doi:10.1371/journal.pone.0098467.g001
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By linear regression analysis, the UGT1A1*28 polymorphism
and body weight were the only factors associated to bilirubin levels
within controls (Ln TB=1.143+0.462 UGT1A1*28 polymorphism
+0.014 weight; standardised Beta: 0.598 and 0.490; p,0.001 and
p=0.001, respectively). Within obese patients, the UGT1A1
polymorphism and body fat percentage were the main determi-
nant factors of bilirubin levels (Ln TB=2.761+0.251 UGT1A1*28
polymorphism 20.020 body fat; standardised Beta: 0.348, 2
0.291; p=0.002 and p=0.009, respectively). For a better
visualization of the results (graphically), obese participants were
divided on the basis of their UGT1A1 genotype and on having a
body fat lower or higher/equal than 42.5% (cut-off that
corresponds to the median value for the obese group; Figure 3).
Discussion
As far as we know, this is the first report assessing the
concomitant influence of UGT1A1*28 polymorphism and adipos-
ity markers on bilirubin levels in obese children and adolescents.
We demonstrated that body fat percentage is a major determinant
of TB levels independently of UGT1A1*28 polymorphism in obese
children and adolescents.
It is known that UGT1A1 polymorphisms are associated with
bilirubin levels and our data are in agreement with previous
reports in young patients and adults [15,28–30]. Patients and
controls with 7/7 genotype presented the highest TB levels,
followed by 6/7 and 6/6 genotypes (Figure 1A and 1B).
The frequency of 7/7 homozygotes (7.5% in the whole
population) was lower than that observed in other works, namely
in healthy Greek [29] and Slovenian [30] populations, with
frequencies of 14.8% and 13.6%, respectively. However, the
distribution of subjects with respect to UGT1A1 genotypes was
similar to that found in previous studies involving Portuguese
children with Hereditary Spherocytosis, with a 7/7 frequency of
8.8%(28), as well as Portuguese healthy subjects, with frequencies
observed in two studies of 6.3 and 9.9% [28,31]. Thus, it seems
reasonable to assume that the frequency of 7/7 homozygotes in
the Portuguese population may be lower than that observed in
other Caucasian populations.
Other potential variables could influence TB levels. Within both
controls and obese patients TB levels were positively and
Table 2. Anthropometric data, UGT1A1*28 polymorphism, haematological and biochemical parameters of obese patients
according to body fat percentage (n= 74) lower or higher/equal than 42.5% (median value for the obese group).
Obese patients (n=74)
Body fat #42.5% Body fat .42.5% p
Number of participants 37 37
Female, n (%) 13 (35.1%) 21 (56.8%) 0.102
Age (years) 11.063.0 9.562.5 0.022
Height (cm) 149.2614.3 144.0614.2 0.126
Weight (kg) 59.8618.9 61.4623.9 0.749
BMI (kg/m2) 26.064.0 28.465.5 0.041
BMI z-score 1.9860.24 2.3160.26 ,0.001
Body fat (%) 36.864.3 46.162.6 ,0.001
Trunk fat (%) 34.565.5 45.363.4 ,0.001
UGT1A1 genotype
6/6, n (%) 21 (56.8%) 19 (51.4%) 0.359
6/7, n (%) 14 (37.8%) 18 (48.6%)
7/7, n (%) 2 (5.4%) 0 (0%)
RBC (61012/L) 4.8360.38 4.9160.34 0.389
Hb (g/dL) 13.961.0 13.660.8 0.268
Ht (L/L) 0.4160.03 0.4160.02 0.798
MCV (fL) 85.464.9 83.864.6 0.156
MCH (pg) 28.761.7 27.861.5 0.017
MCHC (g/dL) 33.660.8 33.260.9 0.020
Total bilirubin (mmol/l) 11.29 (8.72–14.36) 8.89 (7.69–11.63) 0.013
Acute phase protein
CRP (mg/L) 1.31 (0.84–2.30) 2.00 (1.43–3.54) 0.017
Glucose metabolism
Glucose (mg/dl) 83.567.6 81.068.6 0.191
Insulin (mU/ml) 11.6 (8.9–14.6) 15.3 (7.5–22.9) 0.272
HOMAIR 2.25 (1.91–3.01) 3.15 (1.57–4.56) 0.361
Values are given as mean 6 SD or median (interquartile range), unless otherwise indicated.
BMI, body mass index; RBC, red blood cells; Hb, haemoglobin; Ht, haematocrit; MCV, mean cell volume; MCH, mean cell haemoglobin; MCHC, mean cell haemoglobin
concentration; CRP, C-reactive protein; HOMAIR, homeostasis model assessment insulin resistance.
doi:10.1371/journal.pone.0098467.t002
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significantly correlated with age, height, weight, BMI, and Ht.
However, BMI z-score, body fat and trunk fat percentages were
negatively and significantly related with TB levels in obese
patients, but not within controls. In multiple regression analysis,
the UGT1A1*28 polymorphism and body weight were the only
factors associated to bilirubin levels within controls, whereas the
UGT1A1*28 polymorphism and body fat percentage were the
main determinant factors of bilirubin levels within obese patients.
In the present study, the evaluation of body composition by
DEXA was performed in a subgroup of participants. Despite the
lower number of participants in this sub-analysis, the negative
relation between bilirubin and body fat percentage was highly
statistically significant and independent of the effect of
UGT1A1*28 polymorphism. Furthermore, this negative relation
is in agreement with a previous study involving 41 lean and obese
adult men and women [23].
Bilirubin derives mainly from the haem present in Hb, released
during breakdown of senescent erythrocytes [1]. Thus, in healthy
conditions, it would be assumed that increases in Hb levels are
generally associated with increases in TB. This explains our
positive association between the age of the participants and TB, as
in young individuals there is a physiological increase in Hb levels
with age. It is well known that Hb and Ht increase substantially
during childhood, whereas RBC count remains almost constant
[32]. Differences according to gender become prominent in the
second decade of life; with menstruation, these three variables tend
to be lower in females. The inclusion in our study of subjects with a
range of age between 4 and 18 years old justifies the higher values
of RBC and Hb observed in males within both controls and obese
patients (Table 1). The differences were particularly evident in
obese patients, not only because of the large number of subjects
included in this group but also due to the enhanced puberty
development in obesity. Actually, the increasing prevalence of
obesity in children worldwide is a major cause of precocious
pubertal maturation, verified during the past decades [33].
Total and direct bilirubin levels were reported to be higher in
normal weight adult males than in females [24,34,35], but similar
within overweight patients [24]. In our study, we observed no
statistical significant differences between boys and girls regarding
TB levels, either in controls or in obese patients. Within these two
groups, males and females were matched for age, weight, BMI and
distribution of UGT1A1 genotypes (Table 1) and, therefore, the
analysis of TB was not greatly affected by these factors.
In the present manuscript, obese patients and controls were
matched for age and distribution of UGT1A1 genotypes, allowing
the comparison of groups. Independently of gender, obese patients
presented higher RBC count, Hb levels and Ht values compared
with controls (Table 1). The higher weight and BMI in obese
patients trigger the stimulation of erythropoiesis in order to supply
adequate oxygenation to increased body tissues. The lower values
of MCHC in those with higher body fat (Table 2) show a reduced
hemoglobinization of the erythrocytes, suggesting an underlying
disturbance in iron metabolism that might be due to a higher
degree of inflammation presented by these individuals (signifi-
cantly higher CRP), which may interfere with iron absorption and
iron mobilization for erythropoiesis [36].
Despite higher RBC count and Hb levels in obese patients, TB
levels were similar between groups. A speculative explanation to
this observation is bilirubin consumption occurring in obesity, a
hypothesis shared by others (24); obesity is associated with
increased inflammation [16,37,38] and oxidative stress [39,40],
and bilirubin, presenting antioxidant and anti-inflammatory
Figure 2. Total bilirubin (A) and C-reactive protein (B) levels in obese participants according to gender and to body fat percentage
(n=74), using the cut-off value of 42.5% (cut-off that corresponds to the median value for the obese group). The boxes represent the
interquartile range (IQR), with the upper and lower edges of the boxes representing the 75th and 25th percentiles, respectively. The central horizontal
lines within the boxes represent median levels for each group. The vertical whiskers above and below the boxes represent the range of outlying data
points up to 1.5 times the IQR.
doi:10.1371/journal.pone.0098467.g002
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properties [9,10], may be somewhat consumed. In fact, oxidative
stress increases with increasing BMI and age [34]. In line with this,
we found that bilirubin levels are negatively correlated with body
and trunk fat percentages and CRP levels within obese patients.
Moreover, when obese patients were divided in two groups
according to the median value of body fat presented by this group
(42.5%), patients presenting higher body fat presented lower
bilirubin and higher CRP levels (Table 2). The negative relation
that we found between bilirubin and CRP levels is in line with the
bilirubin’s anti-inflammatory activity, as previously reported [41–
44].
In obese patients, insulin resistance may also underlie the
association between lower bilirubin levels and higher body fat
percentages. Indeed, it seems that the activity of heme oxygenase-
1, the rate-limiting enzyme of bilirubin production, is impaired in
insulin resistant states [45,46]. Also, the up-regulation of heme
oxygenase-1 in adipocyte by insulin was recently demonstrated
[47]. In this work obese patients presented higher HOMAIR values
compared to controls (Table 1). Obese patients with body fat
percentages higher than 42.5% also presented higher HOMAIR
values, although without statistical significance. However, no
significant correlation was obtained between HOMAIR and
bilirubin. Thus, association between insulin resistance and
bilirubin might not be so clear in paediatric populations.
A previous work from our group demonstrated that BMI z-score
is significantly and independently related to the lipid profile in
obese children and adolescent [48]. However, in the present study
BMI z-score was poorly related with TB levels in obese patients
and it was not an independent predictor of bilirubin plasma
concentration. This suggests that body fat percentage is a better
indirect marker of oxidative stress, rather than BMI z-score.
Actually BMI z-score is calculated using the BMI of patients,
adjusted to age and gender, but it may not necessarily express the
degree of obesity.
Figure 3. Effect of body fat percentage on total bilirubin levels according to UGT1A1*28 polymorphism on obese patients. For a
better visualization of the results we used for body fat percentage a cut-off of 42.5% (cut-off that corresponds to the median value for the obese
group). Results are presented as mean 6 standard error of mean. The influence of body fat percentage, adjusted for UGT1A1 polymorphism, on total
bilirubin levels, was highly significant (p= 0.009), by multiple regression analysis.
doi:10.1371/journal.pone.0098467.g003
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Individuals with a higher physical fitness index (which serves as
an aerobic assessment) seem to present with higher bilirubin levels
[24] and a study performed in overweight and obese adult patients
demonstrated an increase in bilirubin levels due to short-term
weight loss [35]. It seems that high doses of exercise training are
necessary to significantly increase bilirubin levels in overweight
and obese women [49]. The fact that bilirubin levels increase as a
function of weight loss may be of particular importance in obese
individuals with UGT1A1 genotypes associated to lower bilirubin
levels, as we here demonstrated effects on TB by body fat
composition in addition to the UGT1A1*28 polymorphism. It is
important to keep in mind that atherosclerosis is a multifactorial
disease that initiates early in life, involving the interplay of genetic
and environmental factors. The lifestyle improvement is condi-
tioned by environmental factors (such as nutritional behaviour and
practice of physical activity) and may be particularly worthy in
obese individuals with a less favourable genetic background.
Despite the new data reported here, this work presented some
limitations. Obesity was defined according to CDC although a
novel criteria is now recommended for the Portuguese population,
causing us to have probably underestimated the degree of obesity.
Nevertheless, at the beginning of this study the criteria recommend
by the Portuguese Ministry of Health was that of CDC. Also, the
number of controls was small to evaluate UGT1A1 genotype
distribution in cases and controls; actually, besides ethics
requirements, parental approval in healthy children and adoles-
cents is difficult to obtain. The evaluation of body composition by
DEXA was also performed only in a subgroup of participants due
to logistical constraints and equipment availability. Furthermore,
we did not evaluate the association between bilirubin and the MS
as a large proportion of our obese patients were under the age of
10, not allowing their classification according to the International
Diabetes Federation (IDF) definition.
In conclusion, body fat percentage is a major determinant of TB
levels independently of UGT1A1*28 polymorphism in obese
children and adolescents. This may have a particular relevance,
as obese individuals, particularly those with 6/6 UGT1A1
genotype and higher body fat mass, may benefit from a closer
clinical follow-up, considering their increased risk for other
comorbidities. Moreover, lifestyle modifications at low ages, when
good habits can be created, should be highly encouraged in such
obese children and adolescents.
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